Allergy Treatment Market – Global Market Size, Strategic Growth Drivers, Risk Assessment Framework, Regulatory Landscape Review, Competitive Intensity Mapping & Long-Term Industry Outlook to 2032
Overview
Global Allergy Treatment Market size was valued at USD 24.6 Bn. in 2024, and the total Allergy Treatment Market is expected to grow by 7.2 %. from 2025 to 2032, reaching nearly USD 42.9 Bn.
Allergy Treatment Market Overview
The allergy treatment market comprises a wide range of products and therapies aimed at diagnosing, managing, and alleviating allergic conditions. This includes drugs such as antihistamines, corticosteroids, and biologics, as well as immunotherapies like allergy shots and sublingual tablets, alongside diagnostic tools and devices used across hospitals, clinics, and homecare settings.The Allergy Treatment Market is experiencing significant growth, driven by rising allergy prevalence, technological innovations, and shifting patient preferences. North America currently leads the market, supported by advanced treatment options, favorable reimbursement, and strong healthcare infrastructure. Meanwhile, Asia-Pacific is the fastest-growing region, fueled by urbanization, pollution, and rising disposable incomes in countries like India and China. While food and skin allergy treatments represent the fastest-growing segments, supported by changing dietary habits and heightened awareness. Innovation is a key driver, with advances in biologics, personalized medicine through gene profiling, and user-friendly diagnostic kits enhancing outcomes. Digital health tools, mobile apps, and telemedicine are further transforming patient engagement and access to care.
To know about the Research Methodology :- Request Free Sample Report
The FDA approval of omalizumab (Xolair) for food allergies and Beckman Coulter’s multiplex allergy assays, illustrate the sector’s rapid progress. Together, these factors position the market for robust growth, offering opportunities for global pharma leaders and specialty biotech firms alike.
Allergy Treatment Market Dynamics:
Rising Prevalence of Allergic Rhinitis & Asthma to drive the Allergy Treatment Market
Environmental factors and urbanization are key contributors, as increasing air pollution in megacities from Beijing to Delhi triggers immune responses, raising the risk of these conditions. Sensitization rates in such cities exceed 50%, while globally, allergic rhinitis affects up to 30% of adults and 40% of children, creating a substantial and consistent patient base for allergy therapies. Climate change further intensifies demand, with longer pollen seasons and altered allergen distribution leading to more frequent and severe allergic episodes. Lifestyle changes, including increased indoor time and higher exposure to dust mites, pet dander, and pollutants, are also driving incidence rates. Genetic predisposition amplifies susceptibility, contributing to the overall market potential.
Technological advancements like telemedicine, mobile symptom trackers, and digital health platforms are encouraging patients to seek treatment and adhere to therapy plans, expanding market reach. Globally, asthma prevalence varies significantly, from 3.3% in Pakistan to 14.3% in Saudi Arabia, while urban pollution in cities like Beijing has increased asthma rates from 11.1% to 17.6% in six years. This growing patient population, coupled with the availability of over-the-counter drugs, second-generation antihistamines, and innovative biologics such as omalizumab, is boosting market demand. Rising healthcare costs and productivity losses also motivate governments and patients to adopt better treatment options. The escalating prevalence of asthma and allergic rhinitis is a major driver of the global allergy treatment market.
Expanding R&D and Innovative Therapies creates growth opportunities in Allergy Treatment Market
The increasing focus on research and development in allergy treatments is creating significant growth opportunities in the global allergy treatment market. Researchers are exploring diverse approaches, including allergen immunotherapy, DNA- and virus-such as particle-based vaccines, biologics such as anti-IgE antibodies, and advanced cell and gene therapies. Rising adoption of biologics and regenerative medicine provides new pathways for innovative drug development. Investment in R&D is accelerating through public-private partnerships and increased funding, driving advancements in both treatment efficacy and patient accessibility. Tele-immunotherapy has emerged as a transformative channel, increasing from 17% usage before the pandemic to 89% during lockdowns, signaling a long-term shift in treatment delivery.
Advanced technologies, such as AI-based allergen and pollen forecasting, enable real-time dose titration, enhancing safety and treatment outcomes. Sublingual immunotherapy (SLIT) tablets have gained traction due to their comparable efficacy with subcutaneous injections, fewer injection-site reactions, and improved patient compliance. Inclusion in pharmacy-benefit listings further reduces barriers, increasing accessibility. These developments in R&D, digital health integration, and patient-friendly therapies are driving incremental market growth, positioning the global allergy treatment market for sustained growth and innovation.
Allergy Treatment Market Segment Analysis:
Based On Allergy Type, Allergy Treatment Market is segmented into Eye Allergy, Rhinitis Asthma, Skin Allergy, Food Allergy and Other Allergies. The rhinitis segment dominated the Allergy Type segment in 2024. Due to high prevalence and growing patient awareness. Allergic rhinitis, caused by airborne allergens such as pollen, dust mites, and pet dander, affects millions worldwide, particularly in urbanized regions with rising pollution levels. Sensitization rates in key cities often exceed 50%, creating a large and consistent patient base for treatments.
Environmental factors, including air pollution, climate change, and longer pollen seasons, have intensified symptom frequency and severity, boosting demand for both prescription and over-the-counter therapies. Advances in treatment options, such as second-generation antihistamines, intranasal corticosteroids, and sublingual immunotherapy (SLIT), have improved efficacy and patient compliance, making management easier and more effective. Increasing digital health adoption, telemedicine consultations, and public awareness campaigns have facilitated early diagnosis and treatment initiation. Together, these factors contribute to the rhinitis segment’s dominant market share, reflecting both the widespread impact of the condition and growing therapeutic adoption globally.
Based on End User, Allergy Treatment Market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Retailers, Others. The Hospital Pharmacies segment dominated the End User segment in 2024.Due to its critical role in providing specialized care and access to advanced allergy therapies. Hospitals are primary points for diagnosis, treatment initiation, and management of moderate-to-severe allergic conditions such as asthma, rhinitis, and skin allergies. This ensures a steady and substantial demand for prescription medications, biologics, and immunotherapy treatments.
The presence of trained healthcare professionals enables accurate prescription, monitoring, and patient education, which is particularly important for complex treatments like biologics and subcutaneous or sublingual immunotherapy.
Additionally, hospital pharmacies often have established supply chains, bulk procurement advantages, and partnerships with pharmaceutical manufacturers, ensuring consistent availability of allergy medications. Rising patient awareness, increasing prevalence of chronic allergies, and the growing adoption of hospital-based specialty treatments further reinforce the dominance of hospital pharmacies. Their capacity to deliver both emergency and routine allergy care makes them the most preferred and trusted channel in the Allergy Treatment Market.
Allergy Treatment Market Regional Analysis:
North America dominated the Allergy Treatment Market in 2024. This leadership is driven by strong economic, clinical, and regulatory factors that enable wider patient access and early adoption of advanced therapies. Extensive insurance coverage in the U.S. and Canada supports diagnostics, prescription medications, immunotherapies, and biologics, facilitating high patient uptake. Early adoption of novel therapies has positioned North America as a global launch hub. The FDA approved omalizumab (Xolair) for multiple food allergies and Palforzia, the first oral peanut allergy immunotherapy, in 2024, enabling immediate clinical rollout across hospitals and specialty clinics. Concentrated networks of allergists and immunologists ensure precise diagnostics, personalized treatments, and management of severe allergic conditions such as asthma and rhinitis.
Technological innovations and digital health integration further strengthen the market. Multiplex allergy assays and AI-driven pollen forecasting streamline diagnosis and optimize dosing, while EHR-integrated platforms and tele-immunotherapy improve patient adherence and outcomes. Strategic partnerships between biotech firms have accelerated the development of oral mucosal immunotherapies and advanced biologics, particularly for complex allergies. Public awareness campaigns, advocacy by organizations like the Asthma and Allergy Foundation of America, and patient-driven demand for personalized therapies reinforce high adoption rates. Combined with a regional market valuation surpassing $10.88 billion in the U.S., these factors underscore North America’s leadership in advancing allergy treatment accessibility, innovation, and clinical outcomes globally.
Allergy Treatment Market Competitive Analysis:
The global allergy treatment market in 2024 is highly fragmented, with strong competition between pharmaceutical giants and specialized biotech firms. Major players include Johnson & Johnson, Sanofi, GSK, Novartis, Pfizer, Teva, AbbVie, Bayer, AstraZeneca, and Roche, alongside niche innovators such as ALK-Abelló, Stallergenes Greer, and Allergy Therapeutics. These companies lead across key segments including anti-allergy drugs, immunotherapy, food allergy treatments, and diagnostics.Anti-allergy drugs remain the largest revenue driver, dominated by firms like Sanofi, GSK, and Novartis, while immunotherapy specialists ALK-Abelló and Stallergenes Greer pioneer SLIT tablets and oral immunotherapy. Food allergy treatments are gaining traction with Palforzia and multi-allergen biologics like omalizumab. Diagnostics leaders such as Thermo Fisher and Beckman Coulter are enhancing patient care through multiplex assays and digital platforms. Key trends shaping competition include aggressive R&D partnerships, biosimilar launches, device innovation (e.g., nasal epinephrine sprays), and digital differentiation. With diversified portfolios and strong pipelines, leading companies continue to expand global access, driving market growth
Allergy Treatment Market Key Trends:
1. Rise of Biologics and Targeted Immunotherapies
Biologics, such as anti-IgE antibodies, and advanced immunotherapy options are transforming allergy management. These therapies target specific immune pathways, offering effective treatment for severe or persistent allergic conditions like asthma, rhinitis, and food allergies. Increased FDA approvals, growing clinical adoption, and expanding patient access are driving market growth, with hospitals and specialty clinics leading the uptake.
2. Digital Health Integration and Telemedicine Expansion
The adoption of digital health tools, including tele-immunotherapy, AI-based allergen forecasting, mobile symptom trackers, and EHR-integrated platforms, is enhancing patient monitoring, adherence, and real-time dose adjustments. Telemedicine usage surged during the COVID-19 pandemic, shifting long-term treatment delivery toward remote and hybrid care models. This trend improves patient convenience, reduces healthcare costs, and expands reach in underserved regions, creating a significant growth avenue for the allergy treatment market.
Allergy Treatment Market Key Development:
May 16, 2024, Johnson & Johnson acquire Proteologix, Inc. for $850 million, plus potential milestones, strengthening its immunology pipeline with bispecific antibodies for atopic dermatitis (AD) and asthma. Key assets include PX128, entering Phase 1, and PX130 in preclinical development. The acquisition expands J&J’s innovative therapies targeting multiple pathways to achieve durable remission in immune-mediated diseases.
July 31,2025, Allergy Therapeutics, a fully integrated commercial biotechnology company focused on allergy immunotherapies, announced the publication of three key studies in Allergy, the official EAACI journal with an impact factor of 12.6. The publications highlight the efficacy, safety, and quality-of-life benefits of Grass MATA MPL, the company’s innovative SCIT candidate for grass pollen-induced allergic rhinoconjunctivitis.
June 2, 2025, Sanofi will acquire Blueprint Medicines for $9.1 billion, with potential milestone payments raising the deal to $9.5 billion. The acquisition adds Ayvakit/Ayvakyt, the only approved therapy for advanced and indolent systemic mastocytosis, alongside elenestinib and BLU-808. This strengthens Sanofi’s immunology portfolio and expands its presence in rare immunological diseases through Blueprint’s established specialist network.
April 23, 2025 ALK has received European approval for ITULAZAX, its tree pollen sublingual allergy tablet, for children and adolescents aged 5–17 across 17 EU countries. Based on positive Phase 3 TT-06 trial results, the approval expands ALK’s immunotherapy portfolio, now covering five major respiratory allergies across all age groups in key global markets.
Allergy Treatment Market Scope: Inquire before buying
| Global Allergy Treatment Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2024 | Forecast Period: | 2025-2032 |
| Historical Data: | 2019 to 2024 | Market Size in 2024: | USD 24.6 Bn. |
| Forecast Period 2025 to 2032 CAGR: | 7.2% | Market Size in 2032: | USD 42.9 Bn. |
| Segments Covered: | by Allergy Type | Eye Allergy Rhinitis Asthma Skin Allergy Food Allergy Other Allergies |
|
| by Treatment Type | Anti-allergy drugs Antihistamines Corticosteroids Decongestants Other drugs Immunotherapy Sub-cutaneous immunotherapy (SCIT) Sub-lingual immunotherapy (SLIT) |
||
| by Route of Administration | Oral Inhalers Intranasal Others |
||
| by Dosage Form | Tablets & Capsules Nasal Sprays Others |
||
| by End User | Hospital Pharmacies Retail Pharmacies Online Retailers Others |
||
Allergy Treatment Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
South America (Brazil, Argentina Rest of South America)
Middle East & Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
Allergy Treatment Key players
North America
1. AbbVie Inc. (US)
2. Johnson & Johnson Services, Inc. (US)
3. Stallergenes Greer (US)
4. Genentech (US)
5. Inimmune Corporation (US)
6. Intrommune Therapeutics (US)
7. Perrigo Company plc (US)
8. Regeneron Pharmaceuticals (US)
Europe
9. GlaxoSmithKline plc (GSK) (UK)
10. Allergy Therapeutics plc (UK)
11. ALK-Abelló A/S (Denmark)
12. Allergopharma (Dermapharm AG) (Germany)
13. Bayer AG (Germany)
14. Boehringer Ingelheim International GmbH (Germany)
15. HAL Allergy Group (Netherlands)
16. Leti Pharma (Spain)
17. AstraZeneca plc (UK)
18. Biomay AG (Austria)
19. Circassia Group plc (UK)
20. ASIT Biotech (Belgium)
21. Anergis SA (Switzerland)
22. DBV Technologies (France)
23. Aimmune Therapeutics (US)
24. Immunomic Therapeutics (US)
25. Nicox S.A. (France)
26. Sanofi S.A. (France)
Allergy Treatment Market Frequently Asked Questions
1. Market Size of Allergy Treatment Market?
Ans: Global Allergy Treatment Market size was valued at USD 24.6 Bn. in 2024, and the total Allergy Treatment Market is expected to grow by 7.2 %. from 2025 to 2032, reaching nearly USD 42.9 Bn.
2. Which region dominated the Allergy Treatment Market?
Ans: North America is the region that dominates the Allergy Treatment Market.
3. What is the study period of this market?
Ans: The Allergy Treatment Market is studied from 2024 to 2032.
4.Who are the primary end users in the allergy treatment market?
Ans: Hospital Pharmacies, Retail Pharmacies, Online Retailers, Others, are the End Users of the Allergy Treatment Market.
